Arangodb crunchbase trial#
Arangodb crunchbase series#

Innoplexus's technology infrastructure is built upon a biomedical ontology created by combining 200 public life science domain ontologies such as Reactome, MeSH, and UMLS. Data Extraction & Computer Vision Ĭrawled and aggregated structured, semi-structured and unstructured data are then extracted from their respective sources using optical character recognition (OCR) and layout analysis which uses machine learning to understand document layout and structure data into a machine-readable format. This data ocean encompasses approximately 97% of all public life science data available. Together, this produces a real-time data ocean containing over 35 million scientific publications, 500,000 clinical trials, 833,000 scientific congress proceedings, 26 million patents, 5 million grants, 1 million theses and dissertations, 73,000 drug profiles, 40,000 gene profiles, 10,000 news organizations, 35,000 treatment guidelines, and 20 million authors. Additionally, Innoplexus aggregates diverse data types from thousands of structured, semi-structured, and unstructured life science databases such as PubMed, EMBL-EBI, and DrugBank. Innoplexus uses machine learning to actively crawl public web domains for life science data. Innoplexus currently has 10 patent applications pending in the United States. Futhermore, Innoplexus is partnered ArangoDB, Hortonworks, NVIDIA, Google Cloud, and Amazon Web Services. Innoplexus's technology stack includes MongoDB, Elasticsearch, and ArangoDB. Innoplexus has routinely been cited as a industry leader the application of artificial intelligence in the life sciences by Gartner in 20. Former Merck KGaA executive, Lawrence Ganti, was appointed as CEO of the Americas. In January 2018, Innoplexus opened its North American flagship office in Hoboken, New Jersey.

Arangodb crunchbase series#

In 2017, Innoplexus raised a Series A funding round from Apeiron Investment Group. Innoplexus also established an office in Pune, India. Innoplexus was founded in 2011 by Gunjan Bhardwaj and Gaurav Tripathi in Frankfurt, Germany with funding from German venture capital firm HCS Beteiligungsgesellschaft.

2.4 Natural Language Processing & Named Entity Disambiguation.Innoplexus's mission is to democratize artificial intelligence, providing solutions to companies that would not otherwise be able to build such systems themselves or to companies that want to augment their existing in-house infrastructure in order to accelerate pharmaceutical innovation. Innoplexus has also designed tools for the legal and financial services industries. Innoplexus is also a member of NVIDIA's Inception Program, an accelerator program that supports exceptional artificial intelligence startups, providing them with expertise and GPU hardware necessary to improve their technologies. Innoplexus is considered one of the most innovative artificial intelligence companies in healthcare.

Arangodb crunchbase trial#

Innoplexus AG is a German artificial intelligence and blockchain company that specializes in the life science-related products designed primarily for the pharmaceutical and biotechnology industries, which include a life science search engine, ontology-based network analytics, sentiment analytics and business intelligence, and clinical trial and regulatory tools. Innoplexus Holdings, Inc., Innoplexus Consulting Services Pvt.